Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor

 
• By Lucie Ellis-Taitt
Racing horse
Tesaro's drug has the potential to overtake AstraZeneca's approved PARP inhibitor Lynparza • Source: Shutterstock/Ogla-i

More from R&D

More from Scrip